Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
STAMFORD, Conn., Nov. 08, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced that members of its management team will deliver company overviews at three investor conferences in November:
Stifel 2017 Healthcare Conference (New York)
Date: Tuesday, November 14, 2017
Time: 11:00 a.m. ET
Jefferies 2017 London Healthcare Conference (London, UK)
Date: Thursday, November 16, 2017
Time: 4:40 p.m. GMT (11:40 a.m. ET)
29th Annual Piper Jaffray Healthcare Conference (New York)
Date: Tuesday, November 28, 2017
Time: 11:00 a.m. ET
A live audio webcast of each event can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. Archived webcast recordings will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by CR845, a first-in-class KOR agonist that targets the body's peripheral nervous system. In Phase 2 trials, CR845 has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in patients with moderate-to-severe chronic kidney disease-associated pruritus. Additionally, CR845 has demonstrated initial efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations
212-362-1200
[email protected]
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
[email protected]
